RxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Reduce" by Analysts

Key Points

• Fifteen analysts give RxSight a consensus recommendation of “Reduce” (3 sell, 10 hold, 2 buy) with an average 12‑month price target of $9.78.
• Institutional investors own 78.78% of the stock, and several large funds recently boosted positions substantially—Millennium (+130.6%), Bank of America (+406.0%), UBS (+183.0%) and Nuveen (+609.7%).
• RXST shares opened at $6.83 (market cap ~$281.9M) and trade well below their 12‑month high of $16.74, while the company commercializes the Light Adjustable Lens for cataract and lens‑replacement patients.

Shares of RxSight, Inc. (NASDAQ:RXST - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the fifteen analysts that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $9.7778.

RXST has been the subject of several analyst reports. Wolfe Research upgraded shares of RxSight to an "outperform" rating in a research note on Friday, January 30th. Needham & Company LLC restated a "buy" rating and issued a $13.00 target price on shares of RxSight in a research note on Thursday, February 26th. William Blair assumed coverage on shares of RxSight in a research note on Friday, January 30th. They issued a "market perform" rating for the company. Stifel Nicolaus reduced their price objective on shares of RxSight from $10.00 to $9.00 and set a "hold" rating on the stock in a research note on Monday, March 9th. Finally, UBS Group increased their price objective on shares of RxSight from $8.00 to $9.00 and gave the company a "neutral" rating in a research note on Thursday, February 26th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RXST. Millennium Management LLC boosted its stake in RxSight by 130.6% during the 3rd quarter. Millennium Management LLC now owns 2,193,062 shares of the company's stock valued at $19,716,000 after acquiring an additional 1,241,885 shares during the last quarter. Bank of America Corp DE boosted its stake in RxSight by 406.0% during the 3rd quarter. Bank of America Corp DE now owns 722,435 shares of the company's stock valued at $6,495,000 after acquiring an additional 579,653 shares during the last quarter. UBS Group AG boosted its stake in RxSight by 183.0% during the 3rd quarter. UBS Group AG now owns 735,170 shares of the company's stock valued at $6,609,000 after acquiring an additional 475,395 shares during the last quarter. Nuveen LLC boosted its stake in RxSight by 609.7% during the 4th quarter. Nuveen LLC now owns 531,730 shares of the company's stock valued at $5,541,000 after acquiring an additional 456,803 shares during the last quarter. Finally, 4D Advisors LLC boosted its stake in RxSight by 343.9% during the 3rd quarter. 4D Advisors LLC now owns 554,930 shares of the company's stock valued at $4,989,000 after acquiring an additional 429,930 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors.

RxSight Trading Up 0.9%

Shares of RXST stock opened at $6.83 on Friday. The company has a market capitalization of $281.87 million, a PE ratio of -7.19 and a beta of 1.22. The firm has a fifty day simple moving average of $7.52 and a 200-day simple moving average of $9.09. RxSight has a twelve month low of $5.90 and a twelve month high of $16.74.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company's flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.